M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance PharmaphorumInsilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates.NeuroscienceRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum Insilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Post-marketing oncology studies: Enabling faster recruitment and lower costsNext: Boehringer advances duo for aggressive cancers into phase 3 Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
